Avastin (bevacizumab) / Roche  >>  Phase 2
Welcome,         Profile    Billing    Logout  

685 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Avastin (bevacizumab) / Roche
NCT03641976: A Study of Bevacizumab, Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (A-FOLFOXIRI) Compared With Bevacizumab, Infusional Fluorouracil, Leucovorin, and Irinotecan/Oxaliplatin (A-FOLFIRI/FOLFOX) as First-line Treatment for Metastatic Right-sided Colon Cancer

Recruiting
2
120
RoW
A-FOLFOXIRI, Arm II (A-FOLFOX/A-FOLFIRI)
Yonsei University
Unresectable Metastatic Right-sided Colon Cancer Starting First-line Combination Chemotherapy, Unresectable Metastatic Right-sided Colon Cancer, Stage IV
06/24
06/24
ChiCTR2100044057: Phase II, single-arm, exploratory clinical study of microwave ablation combined with carrylizumab and bevacizumab for the treatment of advanced liver cancer with recurrence after surgery

Recruiting
2
30
 
Microwave ablation combined with anti-PD-1 antibody and bevacizumab
Affiliated Hospital of Yunnan University (The Second People's Hospital of Yunnan Province); Affiliated Hospital of Yunnan University (The Second People's Hospital of Yunnan Province), CSCO- Qilu Cancer Research Fund
liver cancer
 
 
BRIGHT, NCT05044871: Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer

Not yet recruiting
2
160
RoW
Pamiparib, Bevacizumab, Tislelizumab, Nab paclitaxel, Bevacizumab + Nab paclitaxel (intense dose-dense)
Tongji Hospital, Qilu Hospital of Shandong University, Hubei Cancer Hospital, Hunan Cancer Hospital, Peking University Cancer Hospital & Institute, Obstetrics and Gynecology Hospital of Zhejiang University, Sun Yat-sen University, Anhui Provincial Cancer Hospital, Jilin Provincial Tumor Hospital, First Affiliated Hospital, Sun Yat-Sen University, Affiliated Hospital of Jiangnan University
Ovarian Cancer
06/24
12/27
NCT05678257: A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer

Active, not recruiting
2
182
Europe, US
Fosifloxuridine Nafalbenamide, NUC-3373, Nucleotide analogue, Leucovorin, Folinic acid, LV, Irinotecan, Campto, Camptosar, Bevacizumab, Avastin, Zirabev, 5-FU, 5FU, 5-fluorouracil, Fluorouracil
NuCana plc
Colorectal Cancer, Colorectal Neoplasms, Colorectal Adenocarcinoma, Colorectal Cancer Metastatic, Neoplasm, Colorectal
09/24
03/25
NCT05886465: HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 Trial

Recruiting
2
40
RoW
Atezolizumab, Bevacizumab, HAIC with FOLFOX
Sun Yat-sen University
Hepatocellular Carcinoma
06/24
12/24
NCT05648006: First-line Maintenance of OH2 Injection for Advanced Colorectal Cancer

Terminated
2
7
RoW
OH2, Capecitabine, Bevacizumab
Binhui Biopharmaceutical Co., Ltd.
Advanced Colorectal Carcinoma
04/24
04/24
CBC, NCT05812534: Study of Cadonilimab Combined With Bevacizumab and Chemotherapy for Advanced Nonsquamous Non-small Cell Lung Cancer Patients With Untreated Brain Metastases

Not yet recruiting
2
36
NA
Cadonilimab
Second Affiliated Hospital of Nanchang University, Hunan Cancer Hospital, Fujian Cancer Hospital
Non Small Cell Lung Cancer, Brain Metastases
06/24
06/25
NCT06446206: Adebrelimab Plus Chemotherapy, Bevacizumab and Fluzoparib in Platinum-Sensitive Relapsed Ovarian Cancer

Not yet recruiting
2
22
NA
Adebrelimab, paclitaxel, carboplatin, bevacizumab, fluzoparib
The First Hospital of Jilin University
Platinum-sensitive Relapsed Ovarian Cancer
06/26
06/28
NCT06415851: Chemotherapy Plus Bevacizumab and Anti-PD-1 Followed by Induction Therapy of Chemotherapy Plus Bevacizumab

Not yet recruiting
2
36
RoW
mFOLFOX6 regimen + bevacizumab + PD-1 monoclonal antibody
Zhangfa Song
Metastatic Colorectal Cancer, MSS
05/25
05/26
NCT06341296: Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer

Not yet recruiting
2
86
NA
Irinotecan Liposome, 5-FU, LV, Bevacizumab
West China Hospital
Metastatic Colorectal Cancer
04/26
12/26
NCT06482801: Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT

Recruiting
2
90
RoW
ipilimumab+pembrolizumab or ipilimumab+durvalumab, idarubicin, bevacizumab, Local ICIs.
Second Affiliated Hospital of Guangzhou Medical University
Liver Cancer, Antibody
12/30
12/35
RESOLUTE, NCT05862051: Trial Aims to Investigate the Value of Adding Local Ablative Treatment to Standard Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer

Recruiting
2
75
RoW
Local Ablative Therapy, Standard first-line systemic treatment
Australasian Gastro-Intestinal Trials Group, Walter and Eliza Hall Institute of Medical Research, Cancer Council Victoria
Colorectal Cancer, Oligometastatic Disease
06/24
06/25
TRIFLUOX-DP, NCT06245356: Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer

Not yet recruiting
2
73
NA
Lonsurf, Oxaliplatin, Panitumumab, Bevacizumab, Trastuzumab, Nivolumab
UNICANCER, Servier
Metastatic Colorectal Cancer, Metastatic Gastroesophageal Adenocarcinoma, DPD Deficiency
06/26
06/28
NCT03074513: Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

Active, not recruiting
2
133
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar SCT501, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, Laboratory Biomarker Analysis, Pharmacological Study
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Appendix Adenocarcinoma, Human Papillomavirus-Related Anal Squamous Cell Carcinoma, Human Papillomavirus-Related Cervical Squamous Cell Carcinoma, Human Papillomavirus-Related Squamous Cell Carcinoma of the Penis, Human Papillomavirus-Related Vulvar Squamous Cell Carcinoma, Neuroendocrine Carcinoma, Pancreatic Neuroendocrine Tumor, Recurrent Merkel Cell Carcinoma, Recurrent Nasopharynx Carcinoma, Recurrent Peritoneal Malignant Mesothelioma, Recurrent Pleural Malignant Mesothelioma, Stage III Merkel Cell Carcinoma AJCC v7, Stage III Nasopharyngeal Carcinoma AJCC v7, Stage III Pleural Malignant Mesothelioma AJCC v7, Stage IV Merkel Cell Carcinoma AJCC v7, Stage IV Nasopharyngeal Carcinoma AJCC v7, Stage IV Pleural Malignant Mesothelioma AJCC v7, Stage IVA Nasopharyngeal Carcinoma AJCC v7, Stage IVB Nasopharyngeal Carcinoma AJCC v7, Stage IVC Nasopharyngeal Carcinoma AJCC v7, Vaginal Squamous Cell Carcinoma, Not Otherwise Specified
09/25
09/25
BEAT-MBM, NCT03175432: Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases

Active, not recruiting
2
29
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab awwb, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, BP102, BP102 Biosimilar, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, Cobimetinib, Cotellic, GDC-0973, MEK Inhibitor GDC-0973, XL518, Quality-of-Life Assessment, Quality of Life Assessment
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
BRAF V600 Wild Type, Clinical Stage IV Cutaneous Melanoma AJCC v8, Intracranial Melanoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Refractory Melanoma
06/26
06/26
NCT05170594: A Study of Bevacizumab Combined With Fluzoparib/Chemotherapy or Fluzoparib in the Treatment of Ovarian Cancer

Recruiting
2
60
RoW
Bevacizumab, Antiangiogenic drugs, chemotherapy, Non-platinum chemotherapy, Fluzoparib, PARPi
The Second Affiliated Hospital of Shandong First Medical University
Ovarian Cancer
06/24
06/24
ChiCTR2200061506: Efficacy and safety of portal vein embolization combined with cTACE + camrelizumab + apatinib regimen for conversion therapy of initial unresectable hepatocellular carcinoma

Not yet recruiting
2
40
 
cTACE+camrelizumab+apatinib+PVE ;cTACE+atezolizumab+bevacizumab
The Second Affiliated Hospital, School of Medicine, Zhejiang University; The Second Affiliated Hospital, School of Medicine, Zhejiang University, Jiangsu Hengrui Medicine Co.,Ltd
Hepatocellular Carcinoma
 
 
ChiCTR2300070397: Phase II single-arm, open-label, multicenter study of radiotherapy combined with Bevacizumab treat patients with postoperative residual/recurrent or inoperable desmoid-type fibromatosis who progressed after first-line close observation

Not yet recruiting
2
20
 
Bevacizumab+radiotherapy
Sichuan Cancer Hospital & Institute; Sichuan Cancer Hospital & Institute, Guangzhou Life Oasis Public Service Center
Desmoid-type fibromatosis
 
 
NCT02681549: Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer

Recruiting
2
53
US
Pembrolizumab plus Bevacizumab
Yale University, National Cancer Institute (NCI), Merck Sharp & Dohme LLC
Melanoma, Non-small Cell Lung Cancer, Brain Metastasis
04/25
07/25
NCT02971501: Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases

Active, not recruiting
2
112
US
Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, CT-P16, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Osimertinib, AZD-9291, AZD9291, Mereletinib
National Cancer Institute (NCI)
Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Stage IV Lung Cancer AJCC v8
07/24
07/24
NCT04958811: Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC

Recruiting
2
42
US
Tiragolumab, Atezolizumab, Bevacizumab
Georgetown University, Genentech, Inc.
Non-squamous Non-small-cell Lung Cancer
12/24
12/24
NCT05620771: Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk

Recruiting
2
84
US
Atezolizumab and Bevacizumab, Y90 + TKI
Northwestern University, National Cancer Institute (NCI)
Hepatocellular Carcinoma
07/24
07/25
BBOpCo, NCT06268015: Botensilimab and Balstilimab Optimization in Colorectal Cancer

Not yet recruiting
2
15
US
Botensilimab, Balstilimab, Oxaliplatin, Leucovorin, Fluorouracil, Bevacizumab, Panitumumab
Nicholas DeVito, MD, Gateway for Cancer Research, Agenus Inc.
Colorectal Cancer
07/28
07/28
NCT06401824: Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases

Not yet recruiting
2
25
Europe
Sacituzumab Govitecan-Hziy 180 MG plus bevacizumab, sacituzumab govitecan; zirabev
Maastricht University Medical Center, Gilead Sciences
NSCLC Stage IV, Brain Metastases, Adult
11/26
04/27
VALUE-CHECK, NCT06422403: A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers

Not yet recruiting
2
310
RoW
Extended Dosing Interval - A, Extended Dosing Interval - B, Extended Dosing Interval - C, Standard of Care - A, Standard of Care - B, Standard of Care - C
National University Hospital, Singapore
Carcinoma, Hepatocellular, Gastric Adenocarcinoma, GastroEsophageal Cancer, Oesophageal Cancer, Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
03/29
12/29
NCT05969899: Liposomal Irinotecan Based FOLFIRI With Bevacizumab in First-line Treatment of Advanced Colorectal Cancer

Recruiting
2
50
RoW
FOLFIRI+Bevacizumab
Fudan University
Colorectal Cancer
07/24
02/27
NCT04974879: Osimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Metastatic Non-Small Cell Lung Cancer

Recruiting
2
20
RoW
Osimertinib Oral Tablet, bevacizumab
Qingdao Central Hospital
Carcinoma, Non-Small-Cell Lung
07/24
12/24
BGB-A317-2007, NCT05247619: A Clinical Study to Explore the Efficacy and Safety of Tislelizumab in Combination With Bevacizumab and Chemotherapy in Patients With Persistent, Recurrent, or Metastatic Cervical Cancer

Recruiting
2
49
RoW
Tislelizumab / Bevacizumab/Paclitaxel/Cisplatin/Carboplatin
Zhejiang Cancer Hospital
Cervical Cancer
08/24
01/25
ChiCTR2200062038: A real-world observational cohort study of Tislelizumab in combination with pemetrexed + carboplatin + bevacizumab for EGFR-sensitive mutant non-squamous non-small cell lung cancer patients who have failed EGFR-TKI therapy with negative T790M mutation

Recruiting
2
120
China
Tislelizumab，200mg, d1，Q3W，Until progression or intolerable toxicity ;Pemetrexed，500mg/m2，d1，Q3W，Until progression or intolerable toxicity ;Carboplatin AUC=5(Max：600mg)，d1，Q3W，4 cycles ;Bevacizumab，7.5mg/kg，d1，Q3W，Until progression or intolerable toxicity
XuanWu Hospital, capital medical university ; XuanWu Hospital, capital medical university, Beigene
Non-Small Cell Lung Cancer
 
 
NCT05821361: HAIC Combined With Cadonilimab and Bevacizumab as First-line Therapy in Unresectable Hepatocellular Carcinoma

Not yet recruiting
2
30
RoW
HAIC+Cadonilimab+Bevacizumab
Tianjin Medical University Cancer Institute and Hospital
Unrescetable Hepatocellular Carcinoma
08/24
08/25
CASTLE-01, NCT05010668: Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma

Recruiting
2
25
RoW
cryoablation, Sintilimab, lenvatinib
Fudan University
Intrahepatic Cholangiocarcinoma
08/24
08/24
NCT05551208: Fluzoparib Combined With Bevacizumab in PSROC Previously Treated With PARPi

Recruiting
2
42
RoW
fluzopanib and bevacizumab
Chongqing University Cancer Hospital
Ovarian Cancer
08/24
08/29
TOBACO, NCT05077839: Trifluridine/Tipiracil Combined With Oxaliplatin and Bevacizumab Versus XELOX Plus Bevacizumab in mCRC

Recruiting
2
184
RoW
Trifluridine/Tipiracil, TAS-102
Tianjin Medical University Cancer Institute and Hospital
First-line Treatment, Advanced Colorectal Cancer
08/24
08/25
ChiCTR2200058633: A prospective, single-arm, single-center clinical study of Sintilizumab+bevacizumab combined with standard chemotherapy in the second-line treatment of metastatic colorectal cancer

Not yet recruiting
2
30
 
Sintilizumab combined with bevacizumab
The First Affiliated Hospital of Guangxi Medical University; The First Affiliated Hospital of Guangxi Medical University, Self-financing
Colorectal cancer
 
 
NCT04356729: A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma

Recruiting
2
30
US
Atezolizumab, Tecentriq, Bevacizumab, Avastin, Mvasi
Elizabeth Buchbinder, MD, Genentech, Inc.
Clinical Stage III Cutaneous Melanoma AJCC v8, Stage IV Melanoma, Unresectable Stage III Cutaneous Melanoma, Unresectable Stage IV Cutaneous Melanoma
09/24
09/25
SAHLVE, NCT04101877 / 2018-004438-14: The Sahlgrenska Anti-VEGF Study

Recruiting
2
402
Europe
Bevacizumab Injection, Avastin, Aflibercept Injection, Eylea
Vastra Gotaland Region
Neovascular Age-related Macular Degeneration
09/24
09/24
FFCD 1703 POCHI, NCT04262687: Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate

Recruiting
2
55
Europe
Capecitabine, Oxaliplatin, Bevacizumab, Pembrolizumab
Federation Francophone de Cancerologie Digestive
Colorectal Cancer Metastatic, High Immune Infiltrate, Microsatellite Stable
09/24
09/24
NCT05444374: A Phase II Study of Serplulimab Plus Bevacizumab in Combination With Chemotherapy in 1L Treatment of Untreated Recurrent or Metastatic Cervical Cancer

Not yet recruiting
2
48
RoW
Serplulimab, Bevacizumab
Sichuan Cancer Hospital and Research Institute
Cervical Cancer
09/24
12/25
NCT05819060: The Efficacy and Safety of The Fuzuloparib Combination With Bevacizumab

Not yet recruiting
2
44
RoW
Fuzuloparib Combination with Bevacizumab
Fudan University
Recurrent Ovarian Cancer
09/24
03/25
The AB7 Trial, NCT04829383: A Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma

Active, not recruiting
2
50
US
Atezolizumab, Tecentriq, Bevacizumab, Avastin
Howard S Hochster, Genentech, Inc., Rutgers Cancer Institute of New Jersey
Unresectable Hepatocellular Carcinoma
10/24
10/25
NCT05101629: Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based Therapy

Active, not recruiting
2
32
Europe
Pembrolizumab, Keytruda, Lenvatinib Capsules, Lenvima
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Medizinische Hochschule Hannover, Germany, Prof. Dr. Arndt Vogel, Merck Sharp & Dohme LLC
Hepatocellular Carcinoma
10/24
12/24
MK-4830-002, NCT05446870: Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer

Active, not recruiting
2
160
Europe, Canada, US, RoW
Pembrolizumab, MK-3475, KEYTRUDA®, Paclitaxel, TAXOL®, Carboplatin, PARAPLATIN®, Avastin, Bevacizumab, Zirabev, MVASI, AYBINTIO, Versavo, Onbevezy, OYAVAS, ALYMSYS, Avegra, MK-4830, Docetaxel
Merck Sharp & Dohme LLC
High-grade Serous Ovarian Carcinoma, Ovarian Carcinoma
12/23
12/24
NCI-2018-01503, NCT03587311: Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Active, not recruiting
2
96
Canada, US
Anetumab Ravtansine, BAY 94-9343, Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, CT-P16, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat
National Cancer Institute (NCI)
Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma
10/24
10/24
REGONEXT, NCT05134532: Regorafenib After Progression on Atezolizumab Plus Bevacizumab in Advanced HCC

Active, not recruiting
2
40
RoW
regorafenib
CHA University, Bayer
Hepatocellular Carcinoma
10/24
10/24
SIRTCI, NCT04659382: Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer

Recruiting
2
52
Europe
Atezolizumab, Therasphere, XELOX, Bevacizumab
Federation Francophone de Cancerologie Digestive
Metastatic Colorectal Cancer, pMMR, MSS, Immune Checkpoint Inhibitor, Internal Radiotherapy
10/24
10/24
NCT00200200: Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combination With Chemotherapy With/Without Bevacizumab for Hepatic Metastases From Colorectal Cancer

Active, not recruiting
2
73
US
Bevacizumab HAI plus systemic chemotherapy, HAI plus systemic chemotherapy
Memorial Sloan Kettering Cancer Center
Hepatic Metastases, Colon Cancer, Rectal Cancer
11/24
11/24
NCT03743662: Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma

Active, not recruiting
2
39
US
Re-irradiation (RT), Bevacizumab, Nivolumab, Re-resection
Memorial Sloan Kettering Cancer Center
Glioblastoma
11/24
11/24
NCT04988607: Osimertinib Plus Bevacizumab in Untreated EGFR Exon21 L858R Mutated NSCLC

Not yet recruiting
2
90
RoW
Osimertinib, AZD9291, Tagrisso, Bevacizumab, Avastin
Guangdong Association of Clinical Trials
Lung Cancer
11/24
05/25
NCT05833126: Hepatic Arterial Infusion Chemotherapy in Combination With Atezolizumab and Bevacizumab for Second-line Treatment of Patients With Recurrent Liver Cancer After Liver Transplantation

Recruiting
2
25
RoW
Hepatic arterial infusion chemotherapy + Atezolizumab and bevacizumab
Shuhong Yi
Recurrent Liver Cancer After Liver Transplantation
12/24
04/25
LUMEN-1, NCT06326190: 177Lu-DOTATATE for Recurrent Meningioma

Not yet recruiting
2
135
NA
Local standard of Care, Hydroxycarbamide, Bevacizumab, Sunitinib, Octreotide (Sandostatin LAR), Everolimus, No active treatment (observation with regular follow-up and best supportive care), 177Lu-DOTATATE, ¹⁷⁷Lu-DOTA0-TATE, Lutathera®, Lu oxodotreotide
European Organisation for Research and Treatment of Cancer - EORTC, Novartis
Recurrent Meningioma
04/27
12/28
GEMINI-Hepatobiliary, NCT05775159: Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

Recruiting
2
260
Europe, Japan, US, RoW
Volrustomig, Bevacizumab, Lenvatinib, Rilvegostomig, Gemcitabine, Cisplatin
AstraZeneca
Hepatocellular Carcinoma, Biliary Tract Cancer
11/25
11/26
NCT06439485: Phase II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion

Not yet recruiting
2
25
US
Pemigatinib, Atezolizumab, MPDL3280A, TECENTRIQ, Bevacizumab, Avastin™, Anti-VEGF monoclonal antibody, rhuMAb-VEGF
M.D. Anderson Cancer Center, Incyte Corporation
Advanced Cholangiocarcinoma, FGFR2 Fusion
02/28
02/30
SaINT-ov02, NCT05158062: Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer

Recruiting
2
35
Japan
pembrolizumab, KEYTRUDA, olaparib, LYNPARZA, bevacizumab, AVASTIN, carboplatin, paclitaxel, docetaxel
Kosei Hasegawa, MD, PhD
Carcinoma, Ovarian Epithelial
11/24
11/24
NCT05267288: Phase II Study of Afatinib Plus Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon G719X, S768I, and L861Q Mutation Metastatic Non-Small Cell Lung Cancer

Recruiting
2
30
RoW
afatinib, bevacizumab
Qingdao Central Hospital
PFS
12/24
06/25
ChiCTR2100054182: A Single-Center, Phase II Study of mFOLFOXIRI Combined with Camrelizumab and Bevacizumab in the Neoadjuvant Treatment of Non MSI-H/dMMR Colorectal Cancer

Recruiting
2
32
 
mFOLFOXIRI + Camrelizumab + Bevacizumab
Peking University Shougang Hospital; Peking University Shougang Hospital, The company sponsored the Camrelizumab
Colorectal cancer
 
 
NCT05325229: A Study of Docetaxel for Injection (Albumin-bound) in Combination With Bevacizumab in Patients With Ovarian Cancer

Recruiting
2
94
RoW
Docetaxel for injection (Albumin-bound), Bevacizumab
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Platinum-resistant Recurrent Ovarian Cancer
12/24
12/24
NCT05611645: Low-dose Bevacizumab With HSRT vs BVZ Alone for GBM at First Recurrence

Active, not recruiting
2
42
RoW
Hypofractionated Stereotactic Radiotherapy, Hypofractionated Stereotactic Radiosurgery, Image-Guided Radiation Treatment (IGRT), Stereotactic Radiosurgery (SRS), Bevacizumab, anti-VEGF monoclonal antibody, rhuMAb VEGF, Avastin
Huashan Hospital
Glioma, Recurrent Glioma
12/24
12/25
NCT05760430: The Synergistic Effect of Portal Venous Supply Control and Immunotherapy in Hepatocellular Carcinoma

Recruiting
2
40
RoW
PVE+cTACE+Camrelizumab+Apatinib, cTACE+Atirizumab+Bevacizumab
Second Affiliated Hospital, School of Medicine, Zhejiang University
Hepatocellular Carcinoma
12/24
12/24
NCT05512351: Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Oligodendroglioma

Recruiting
2
80
RoW
Tislelizumab plus Bevacizumab, TYVYT®
Henan Provincial People's Hospital
Oligodendroglioma
12/24
12/26
SLURP, NCT05745857: Oral Bevacizumab-800CW and Cetuximab-800CW Administration to Detect Early Esophageal Adenocarcinomas

Not yet recruiting
2
25
Europe
Avastin, Bevacizumab, Erbitux, Cetuximab, Fluorescence endoscopy and multi-diameter single fiber reflectance/single fiber fluorescence (MDSFR/SFF) spectroscopy
University Medical Center Groningen
Barrett's Esophagus Without Dysplasia, Barrett Oesophagitis With Dysplasia, Esophageal Adenocarcinoma
12/24
12/24
NCT05864755: HAIC Combined With Durvalumab, Tremelimumab and Bevacizumab as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma

Recruiting
2
30
RoW
HAIC+Durvalumab+Tremelimumab+Bevacizumab
Tianjin Medical University Cancer Institute and Hospital
Unrescetable Hepatocellular Carcinoma
12/24
12/25
NCT05540275: Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma

Not yet recruiting
2
30
RoW
Tislelizumab plus Bevacizumab
Henan Provincial People's Hospital
Recurrent Glioblastoma
12/24
12/26
INTEGRATE, NCT04563338: An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases

Recruiting
2
36
Canada
Atezolizumab, TECENTRIQ, Bevacizumab, AVASTIN
University Health Network, Toronto, Hoffmann-La Roche
Hepatocellular Carcinoma, Non-small Cell Lung Cancer Metastatic, Liver Metastases
12/24
12/24
NCT05296278: Efficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC

Recruiting
2
70
RoW
IBI-323 combined with bevacizumab plus Platinum
Hunan Province Tumor Hospital
Non Small Cell Lung Cancer
12/25
04/26
NCT05757336: Combination of Gemcitabine, Albumin-paclitaxel , Sintilimab and Bevacizumab in Unresectable Gallbladder Cancer

Recruiting
2
50
RoW
Combination of Gemcitabine, Nab-paclitaxel, Sintilimab and Bevacizumab
Lu Wang, MD, PhD
Gallbladder Cancer, Initially Unresectable, the First Line Treatment
12/24
12/26
GECP 20/01_Neo-DIANA, NCT04512430: Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients

Recruiting
2
26
Europe
Atezolizumab, Tecentriq, Bevacizumab, Avastin, Carboplatin, Paraplatin, Pemetrexed, Alimta
Fundación GECP
Non Small Cell Lung Cancer, EGFR Gene Mutation
12/24
12/25
BRAIN, NCT05303259: Effect of Bevacizumab on Asymptomatic Radiotherapy-induced Brain Injury

Recruiting
2
204
RoW
Bevacizumab
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Brain Injuries
12/24
12/25
NCT05398861: Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer

Not yet recruiting
2
71
NA
Utidelone Combined with Bevacizumab, UTD1
Henan Cancer Hospital, Qilu Pharmaceutical Co., Ltd., Beijing Biostar Technologies, Ltd
HER-2 Negative Breast Cancer
12/24
12/24
NCT05638451: Sintilimab in Combination With Bevacizumab and Temozolomide in Recurrent Glioblastoma (GBM) Patients

Recruiting
2
30
RoW
Sintilimab plus Bevacizumab and Temozolomide
Zhujiang Hospital
Recurrent Glioblastoma
12/24
12/24
NCT04147351: A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors.

Active, not recruiting
2
22
RoW
Atezolizumab Injection; bevacizumab Injection
National Taiwan University Hospital
NSCLC Stage IIIB~IV
12/24
12/24
ChiCTR2000039535: Irinotecan and retetrasse combined with radiotherapy with or without bevacizumab in patients with recurrent colorectal cancer: a multicenter, prospective, randomized controlled clinical trial

Recruiting
2
220
 
Irinotecan was given intravenously at week 1, week 3 and week 5, 180 mg / m2; Retetrasse was given intravenous drip of 2 mg / m2 for 1 day at 1, 3 and 5 weeks; Concurrent radiotherapy: IMRT external radiotherapy. ;Irinotecan was given intravenously at week 1, week 3 and week 5, 180 mg / m2; Retetrasse was given intravenous drip of 2 mg / m2 for 1 day at 1, 3 and 5 weeks; Bevacizumab was given intravenously for 1 day at week 1, 3 and 5; Concurrent radiotherapy: IMRT external radiotherapy.
The Second Affiliated Hospital, Medical School of Xi'an Jiao Tong University; The Second Affiliated Hospital, Medical School of Xi'an Jiao Tong University, Self financing by researchers
colorectal cancer
 
 
ChiCTR2100051939: Bevacizumab in combination with immune checkpoint inhibitors for the treatment of unrecectable or metastatic highly microsatelite unstable or mismatch repair defective colorectal cancer: a muti-center, single-arm exploratory clinical study

Not yet recruiting
2
51
 
None
Qilu Hospital of Shandong University; Qilu Hospital of Shandong University, Qilu Hospital of Shandong University
Colorectal Cancer
 
 
ChiCTR2100047576: Bevacizumab in combination with immune checkpoint inhibitors for the treatment of unresectable or metastatic highly microsatellite unstable or mismatch repair defective colorectal cancer: a multi-center, single-arm exploratory study

Recruiting
2
60
 
Bevacizumab and Pd-1 monoclonal antibody
Qilu Hospital of Shandong University; Qilu Hospital of Shandong University, self-funded
Colorectal cancer
 
 
NCT05191784: GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) Patients

Active, not recruiting
2
20
RoW
GX-I7, rhIL-7-hyFc, Efineptakin alfa, Bevacizumab, Avastin
Genexine, Inc.
Recurrent Glioblastoma
12/24
12/24
ChiCTR2200059627: Bevacizumab or sintilimab for the refractory and aggressive Recurrent Respiratory Papillomatosis

Not yet recruiting
2
80
 
Bevacizumab ; Bevacizumab ;sintilimab ;Bevacizumab+sintilimab
Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences; Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, partly by Innovent Biologics Inc，partly by Jiangsu Hengrui Pharmaceuticals Co
Recurrent Respiratory Papillomatosis
 
 
ACCRU-GI-2008, NCT05168163: Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer

Recruiting
2
122
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Cabozantinib, Lenvatinib, E7080, ER-203492-00, Multi-Kinase Inhibitor E7080
Academic and Community Cancer Research United, National Cancer Institute (NCI), Genentech, Inc.
Locally Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
12/24
12/26
NCT04981509: Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

Recruiting
2
65
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, CT-P16, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Computed Tomography with Contrast, Contrast Enhanced Computed Tomography, CONTRAST ENHANCED CT SCAN, Contrast-enhanced Computed Tomography, CT Scan With Contrast, CT with Contrast, Erlotinib, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Sodium Fluoride F-18, 18 F-NaF, F-18 NaF, Fluorine F 18 Sodium Fluoride, NaF F18, Sodium Fluoride F18
National Cancer Institute (NCI)
Hereditary Leiomyomatosis and Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Renal Cell Carcinoma, Sporadic Papillary Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
12/24
12/24
NCT04541173: Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)

Terminated
2
6
US
Y-90 TARE, Atezolizumab, Tecentriq, Bevacizumab, Avastin
Aiwu Ruth He, MD, Georgetown University, Genentech, Inc.
Hepatocellular Carcinoma
06/23
06/23
AB-LATE02, NCT04727307: Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II Trial

Recruiting
2
202
Europe
Atezolizumab (neoadjuvant), Tecentriq, Percutaneous Radiofrequency, Bevacizumab (adjuvant), Avastin 400 mg in 16 ml Injection, Avastin 100 mg in 4 ml Injection, Atezolizumab (adjuvant)
University Hospital, Montpellier
Hepatocellular Carcinoma
01/25
07/27
INTERACT-II, NCT06003998: Intraperitoneal Irinotecan With Concomitant FOLFOX and Bevacizumab

Recruiting
2
85
Europe
Irinotecan, Intraperitoneal irinotecan, FOLFOX regimen, 5-FU + oxaliplatin, Bevacizumab, Avastin
Catharina Ziekenhuis Eindhoven
Colorectal Cancer, Peritoneal Metastases
01/25
01/25
NCT05750030: FMT in IT-refractory HCC - FAB-HCC Pilot Study

Recruiting
2
12
Europe
FMT combined with Atezolizumab plus Bevacizumab
Medical University of Vienna
Hepatocellular Carcinoma
01/25
01/26
LOST-B, NCT05537402: LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC

Recruiting
2
204
US
Atezolizumab and bevacizumab, transarterial chemoembolization (TACE) or transarterial radioembolization (TARE
University of Texas Southwestern Medical Center, Genentech, Inc.
Hepatocellular Carcinoma
01/25
01/28
NCT04787289: A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer

Recruiting
2
244
Canada
Bevacizumab
British Columbia Cancer Agency
Ovarian Cancer, Platinum-resistant Ovarian Cancer
01/25
01/25
NCT05211323: A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer

Active, not recruiting
2
88
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, CT-P16, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Conventional Magnetic Resonance Imaging, Conventional MRI, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY-188011, LY188011
National Cancer Institute (NCI)
Combined Hepatocellular Carcinoma and Cholangiocarcinoma, Stage III Liver Cancer, Stage IV Liver Cancer
01/25
01/25
BRISK, NCT05904457: A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer

Recruiting
2
32
RoW
bevacizumab, onbevzi, erlotinib, eltinib
Asan Medical Center, Korean Cancer Study Group, Boryung Pharmaceutical Co., Ltd
Solid Tumors, Advanced Solid Tumors, Metastatic Cancer
01/25
01/26
NCT06063070: First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer

Not yet recruiting
2
44
RoW
Fluzoparib Capsules, Poly (ADP-ribose) polymerase (PARP) inhibitor, Bevacizumab, Antiangiogenic agents
Sun Yat-sen University
Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, High Grade Endometrioid Ovarian Cancer, Primary Peritoneal Cancer, Fallopian-tube Cancer
01/25
10/27
NCT05998941: A Trial of TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer

Withdrawn
2
39
RoW
TQB2868 injection, Paclitaxel injection, Cisplatin injection, Carboplatin injection, Bevacizumab injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Cervical Cancer
02/25
06/25
NCT06039202: Phase 2 Study of CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Relapsed and/or Refractory Metastatic Colorectal Cancer

Not yet recruiting
2
100
NA
CA102N, Nim-HA cinjugate, TAS-102, Trifluridine/tipiracil, Bevacizumab
Holy Stone Healthcare Co., Ltd
Metastatic Colorectal Cancer
02/25
10/25
FOCUS-C, NCT05334277: Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA

Recruiting
2
280
RoW
Furmonertinib, AST2818, Furmonertinib/Pemetrexed/Carboplatin, Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab
Sun Yat-sen University, Allist Pharmaceuticals, Inc., GeneCast Biotechnology Co., Ltd.
Non-small Cell Lung Cancer
02/25
02/28
DEMAND, NCT04224636: Atezolizumab/Bevacizumab Followed by On-demand TACE or Initial Synchronous Treatment With TACE and Atezolizumab/Bevacizumab

Recruiting
2
106
Europe
Atezolizumab Injection, Bevacizumab Injection, Chemoembolisation (TACE)
Ludwig-Maximilians - University of Munich
Hepatocellular Carcinoma Non-resectable
03/25
03/25
NCT05776875: Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC

Recruiting
2
24
US
Atezolizumab Injection, Tecentriq, Bevacizumab, Avastin, Transarterial chemoembolization, TACE
Yale University, Genentech, Inc.
Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma
03/25
08/25
NCT06060704: Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.

Recruiting
2
33
RoW
Envafolimab, Trifluridine/Tipiracil, TAS-102, FTD/TPI, Bevacizumab
The First Affiliated Hospital with Nanjing Medical University
Metastatic Colorectal Cancer
03/25
09/25
NCT05305131: Phase II Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer

Not yet recruiting
2
50
RoW
cisplatin and gemcitabine, induction chemotherapy cisplatin, gemcitabine, bevacizumab and pembrolizumab.
National University Hospital, Singapore
Nasopharyngeal Cancer
03/25
03/26
TROPION-PanTumor03, NCT05489211 / 2022-000776-19: Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours

Calendar Jan 2024 - Dec 2024: Data from TROPION-PanTumor03 trial for advanced solid tumors
Recruiting
2
531
Europe, Canada, Japan, US, RoW
Datopotamab deruxtecan (Dato-DXd), DS-1062a, Saruparib, AZD5305, Durvalumab, MEDI4736, IMFINZI, Capecitabine, Xeloda, 5-Fluorouracil, Adrucil, Volrustomig, MEDI5752, Carboplatin, Paraplatin, Leucovorin LV, Folinic acid, Bevacizumab, Avastin, Rilvegostomig, AZD2936, Prednisone/ prednisolone, Prednisolone
AstraZeneca, Daiichi Sankyo
Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Urothelial Cancer, Biliary Tract Cancer
08/26
08/26
ROP4, NCT04634578: Bevacizumab Treatment For Type 1 ROP

Recruiting
2
80
Canada, US
Bevacizumab, Avastin
Jaeb Center for Health Research, Pediatric Eye Disease Investigator Group, National Eye Institute (NEI)
Retinopathy of Prematurity
04/25
12/26
NCT05965154: Calizumab Combined With Bevacizumab and Capecitabine in the Treatment of Head and Neck Squamous Cell Carcinoma

Not yet recruiting
2
22
NA
Carrilizumab, bevacizumab,capecitabine
Second Affiliated Hospital of Guangzhou Medical University
Head and Neck Squamous Cell Carcinoma
04/25
06/25
NCT05965141: Aribulin Combined With Carboplatin and Bevacizumab in the Treatment of Ovarian Cancer

Not yet recruiting
2
38
NA
Aribulin;carboplatin;bevacizumab
Second Affiliated Hospital of Guangzhou Medical University
Ovarian Cancer
04/25
06/25
ChiCTR2300070483: Efficacy of Sintilimab, Bevacizumab plus TACE for the Treatment of Locally Advanced Hepatocellular Carcinoma (HCC): A single-arm, phase II clinical study

Recruiting
2
40
 
TACE+sintilimab+Bevacizumab
The First Affiliated Hospital of Wenzhou Medical University; The First Affiliated Hospital of Wenzhou Medical University, Innovent Biological Inc (Suzhou)
hepatocellular carcinoma
 
 
TERTIO, NCT05528952: Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Recruiting
2
105
Europe
Atezolizumab, Bevacizumab, UCPVax
Centre Hospitalier Universitaire de Besancon, GERCOR - Multidisciplinary Oncology Cooperative Group, PRODIGE
Hepatocellular Carcinoma
04/25
09/27
B-TACE, NCT05883176: TACE Combined With Bevacizumab in HCC (BCLC-B) Beyond Up-To-Seven Criteria

Not yet recruiting
2
35
RoW
Bevacizumab Biosimilar QL 1101, TACE
Sun Yat-sen University
Hepatocellular Carcinoma by BCLC Stage
05/25
07/25
 

Download Options